Internal Medicine

Cardiovascular diseases (CVD) remain the leading cause of global mortality, accounting for one in every two adult deaths worldwide. The rates of CVD-related morbidity, including heart-failure, peripheral arterial disease and nephropathy are increasing as more patients survive hearts attacks, and the population ages. In addition, Metabolic Diseases, specifically Type 2 diabetes (T2D) and obesity, are major health problems that have reached epidemic proportions worldwide. Globally T2D and obesity incidence have more than doubled in the past two decades. Importantly, CVD and T2D impose large economic burdens on the individual patient and on national healthcare systems and economies. Pfizer scientists are eager to work with world-class partners who share our mission to develop novel and differentiated medicines to improve the lives of patients suffering from CVD.

Pfizer is interested in partnering to develop therapeutics, expand our understanding of disease biology, and identify biomarkers that can help us impact:

• CVD (Heart failure, dyslipidemia)
• Diabetes and related disorders such as hyperinsulinemia
• Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), and cirrhosis
• Cachexia as a consequence of chronic illness
• Obesity and related co-morbidities

Specific areas of interest include:

• Metabolic treatments of heart failure (HFrEF, HFpEF)
• Novel therapies that reduce hyperinsulinemia and hyperglycemia
• Novel mechanisms of muscle glucose uptake
• Decreasing hepatic lipid content and inflammation and the development of liver fibrosis in patients with NASH/NAFLD
• Addressing obesity and eating disorders to induce and sustain weight loss
• Novel mechanisms of unintentional weight loss in chronic illness
• Novel biomarkers for both NASH diagnosis and monitoring of disease progression

Not actively seeking partnering opportunities in:

• Anti-thrombotics
• Anti-arrhythmics
• Stable angina treatments